Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial

ABSTRACT: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract, might improve the phenotype of RDEB patients. In a multicentre, rand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Orphanet J Rare Dis
Main Authors: Chiaverini, Christine, Roger, Coralie, Fontas, Eric, Bourrat, Emmanuelle, Bourdon-Lanoy, Eva, Labrèze, Christine, Mazereeuw, Juliette, Vabres, Pierre, Bodemer, Christine, Lacour, Jean-Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807580/
https://ncbi.nlm.nih.gov/pubmed/27015660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-016-0411-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados